Chemical formula: C₂₁H₁₉BrN₄O₂ Molecular mass: 439.313 g/mol PubChem compound: 9867812
Remimazolam is an ultra-short acting benzodiazepine sedative. The effects of remimazolam on the CNS are dependent on the dose administered intravenously and presence or absence of other medicinal products. Remimazolam binds to benzodiazepine sites of gamma amino butyric acid type A [GABAA] receptors with high affinity, while its carboxylic acid metabolite (CNS7054) has approximately 300 times lower affinity for these receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05CD14 | N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CD Benzodiazepine derivatives | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| BYFAVO Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| BYFAVO Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Remimazolam is an active ingredient of these brands:
United States (US)
Croatia (HR)
Estonia (EE)
Finland (FI)
Ireland (IE)
Japan (JP)
Lithuania (LT)
Poland (PL)
Romania (RO)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
